List of Excipients in Branded Drug BLEPH-10

Generic Drugs Containing BLEPH-10

Company	Ingredient	NDC	Excipient
Allergan Inc	sulfacetamide sodium	11980-011	BENZALKONIUM CHLORIDE
Allergan Inc	sulfacetamide sodium	11980-011	EDETATE DISODIUM
Allergan Inc	sulfacetamide sodium	11980-011	HYDROCHLORIC ACID
Allergan Inc	sulfacetamide sodium	11980-011	POLYSORBATE 80

What are the Most Frequently-Used Excipients in BLEPH-10?

# Of NDCs	Excipient
1	BENZALKONIUM CHLORIDE
1	EDETATE DISODIUM
1	HYDROCHLORIC ACID
1	POLYSORBATE 80

BLEPH-10 Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

BLEPH-10 is a prescription ophthalmic solution containing sulfacetamide sodium 10%. Its active pharmaceutical ingredient is an established topical antibacterial with no biologic complexity and limited apparent patent protection. Commercial opportunity therefore depends on formulation differentiation, preservative strategy, packaging, manufacturing reliability, and channel execution rather than molecule exclusivity.

The strongest product concepts are preservative-free unit-dose presentations, low-irritancy multidose systems, and supply-secure generic versions with improved tolerability. The main technical risks are sulfite sensitivity, benzalkonium chloride exposure, pH-driven ocular irritation, precipitation, container compatibility, and microbiological control.

What is BLEPH-10 and how is it regulated?

BLEPH-10 is a sulfacetamide sodium ophthalmic solution at a 10% concentration, equivalent to 100 mg/mL of sulfacetamide sodium. It is indicated for susceptible bacterial infections involving the superficial ocular structures, including conjunctivitis and blepharitis, subject to the product labeling and prescribing information.[1]

Attribute	BLEPH-10 profile
Active ingredient	Sulfacetamide sodium
Strength	10%, 100 mg/mL
Dosage form	Sterile ophthalmic solution
Route	Topical ophthalmic
Regulatory pathway for competitors	ANDA generic pathway, where applicable
Product type	Small-molecule prescription ophthalmic
Biosimilar relevance	None
Primary formulation issues	Preservatives, sulfites, pH, precipitation, sterility
Commercial category	Mature generic ophthalmic antibacterial

The FDA-approved product labeling identifies inactive ingredients used to support chemical stability, pH adjustment, preservation, and ophthalmic usability. Public labeling for sulfacetamide sodium ophthalmic solutions has included sodium thiosulfate, sulfite components, benzalkonium chloride in some presentations, purified water, and pH-adjusting agents.[1][2]

FDA approval of a competing sulfacetamide sodium ophthalmic product generally requires demonstration of pharmaceutical equivalence and bioequivalence through the applicable ophthalmic product standards and ANDA requirements. The formulation must also satisfy sterility, particulate, container-closure, extractables and leachables, and stability requirements.[3]

What excipients are used in BLEPH-10?

The excipient system is built around four technical functions:

1. Maintaining sulfacetamide sodium in solution.
2. Controlling oxidative degradation.
3. Preserving the multidose container.
4. Adjusting the product to an ophthalmically acceptable pH.

Sodium thiosulfate and sulfite components

Sodium thiosulfate and sulfite-type excipients can act as stabilizing agents in aqueous sulfonamide formulations. They may reduce oxidative degradation and help control impurities generated during storage.

The commercial benefit is formulation robustness. The commercial risk is tolerability. Sulfite-containing products carry labeling concerns for patients with sulfite sensitivity, particularly those with asthma. The presence of sulfites can narrow the target population and create a clear differentiation opportunity for a sulfite-free competitor.[1]

A replacement strategy requires more than simply removing the sulfite system. The sponsor would need to establish:

• Assay and degradation-product stability.
• Compatibility with the selected bottle or vial.
• Preservation performance.
• Photostability.
• Freeze-thaw and shipping stability.
• Absence of precipitation during the labeled shelf life.

Benzalkonium chloride

Benzalkonium chloride is a conventional ophthalmic preservative. It is effective at low concentrations and supports multidose packaging, but repeated exposure can cause ocular-surface irritation, epithelial toxicity, dryness, and discomfort. These concerns are relevant in chronic blepharitis, repeated dosing, pediatric use, and patients with compromised ocular surfaces.[4]

For a mature sulfacetamide product, benzalkonium chloride is a weak long-term differentiation point because competitors can use the same preservative. It is more valuable as a target for product improvement.

Possible commercial strategies include:

Strategy	Technical advantage	Commercial limitation
Retain benzalkonium chloride	Lowest development complexity	Limited tolerability differentiation
Reduce preservative concentration	Potentially lower irritation	Requires preservation and stability justification
Use an alternative preservative	May improve ocular-surface profile	Compatibility and regulatory burden
Use a preservative-free multidose container	Better for repeated use	Higher packaging cost and device qualification
Use preservative-free unit-dose vials	Strong tolerability proposition	Higher packaging, fill-finish, and waste cost

pH adjustment

Sulfacetamide sodium solutions may require pH adjustment to maintain solubility and stability. Hydrochloric acid and sodium hydroxide are conventional choices. The pH must balance chemical stability against ocular comfort.

A product positioned as a low-irritation alternative should not optimize pH only for assay retention. The development program should evaluate:

• Ocular comfort after instillation.
• pH drift during storage.
• Osmolality.
• Precipitation after exposure to air.
• Interaction with tear fluid.
• Effect of pH on preservative activity.

Purified water and container-closure system

Purified water is the principal vehicle. The container is part of the formulation strategy because the product is an aqueous ophthalmic solution exposed to oxygen, light, and repeated handling.

A sponsor should assess low-extractable polymer bottles, light-protective packaging, drop-size consistency, tip contamination, and closure integrity. A smaller drop can reduce waste and lower the active dose delivered to the ocular surface without changing the labeled concentration.

What excipient strategy offers the strongest commercial opportunity?

The highest-value strategy is a preservative-free product with a differentiated delivery system.

Preservative-free unit-dose formulation

A single-use vial avoids the need for an antimicrobial preservative and reduces contamination risk after opening. It is suitable for patients who require repeated courses, have ocular-surface disease, or cannot tolerate benzalkonium chloride.

The drawbacks are higher packaging costs, increased secondary packaging, greater shipping volume, and possible adherence issues. Unit-dose packaging also creates a sustainability and disposal concern.

Preservative-free multidose bottle

Modern multidose systems use one-way valves, antimicrobial barriers, or specialized dispensing technology. They can deliver preservative-free medication while maintaining sterility during the in-use period.

This approach creates a stronger defensible product position than a conventional reformulation. Protection may arise from the dispensing system, closure configuration, manufacturing process, or combination-product elements. Patentability would depend on new and non-obvious technical features, not on the use of sulfacetamide sodium itself.

Sulfite-free formulation

A sulfite-free version could target patients concerned about sulfite sensitivity and physicians seeking a more tolerable alternative. The central challenge is replacing the stabilizing function without creating a new impurity or shelf-life problem.

A sulfite-free product is commercially attractive if it maintains the same 10% strength, remains a clear solution, and avoids a meaningful price premium.

Lower-irritation formulation

A formulation with optimized pH, osmolality, drop size, and preservative exposure could compete on comfort. This positioning is especially relevant for blepharitis, which may require repeated application and affects patients with pre-existing ocular-surface irritation.

Clinical superiority claims would require supporting evidence. A sponsor could initially use narrower, factual labeling claims focused on preservative-free status, sulfite-free status, packaging, and dosing convenience.

What patents protect BLEPH-10?

The active ingredient and basic 10% ophthalmic solution are mature technologies. The principal commercial barriers are unlikely to be composition-of-matter patents. They are more likely to involve manufacturing controls, formulation know-how, packaging, and regulatory execution.

Orange Book status

The FDA Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with approved drug products.[3] No meaningful product-specific patent barrier is apparent from the standard public profile of sulfacetamide sodium ophthalmic solutions. A generic applicant should assess the current Orange Book listing for the applicable reference product before filing a Paragraph IV certification.

Protection category	BLEPH-10 risk assessment
Composition-of-matter patent	Low
Basic formulation patent	Low for the legacy solution
Method-of-use patent	Low to moderate, depending on current listings
Device or dispensing patent	Potentially relevant for improved products
Manufacturing patent	Potentially relevant but difficult to identify from labeling
Regulatory exclusivity	No evident modern exclusivity barrier
Biosimilar exclusivity	Not applicable

Paragraph IV challenges

A Paragraph IV challenge could target any listed patent associated with the reference product. For a legacy ophthalmic antibacterial, the likely commercial case would be a paragraph III certification, no-patent certification, or Paragraph IV certification depending on the current Orange Book record.

The value of a Paragraph IV filing would be limited if:

• The reference product has no listed patents.
• Multiple approved ANDAs already compete.
• The market has low reimbursement and low switching friction.
• The reference product has limited current sales.
• The relevant patents cover only a narrow delivery system.

Method-of-use patents

Method-of-use patents could cover treatment of blepharitis, conjunctivitis, or other susceptible ocular infections. Their practical value depends on listing, claim scope, enforceability, and the ability of a generic applicant to use a skinny label.

A generic applicant may seek approval for non-patented indications if the FDA labeling can be carved out without removing the core commercial indication. The commercial effect is limited when physicians prescribe the product broadly for the same active ingredient and dosage form.

When does BLEPH-10 lose exclusivity?

BLEPH-10 is a mature small-molecule ophthalmic product. The relevant loss-of-exclusivity analysis is driven by patent status, regulatory listings, and market competition rather than a near-term statutory exclusivity event.

Exclusivity element	Assessment
New chemical entity exclusivity	Expired or not commercially relevant
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No meaningful current barrier apparent
Biologic exclusivity	Not applicable
Listed patent term	Must be checked in the current Orange Book
Generic entry	Technically feasible through ANDA pathways
Current competitive risk	High if multiple sulfacetamide ophthalmic ANDAs are approved

The absence of a strong patent barrier does not guarantee successful entry. Ophthalmic products require specialized sterile manufacturing, validated fill-finish operations, suitable dropper performance, and reliable supply of packaging components.

What generic entry risks exist for BLEPH-10?

Generic entrants face five primary risks.

Sterile manufacturing

Aqueous ophthalmic products require validated sterilization or aseptic processing. FDA scrutiny can focus on environmental monitoring, container-closure integrity, particulate control, microbial contamination, and data integrity.

Formulation equivalence

A competitor cannot assume that any clear sulfacetamide solution will be accepted as equivalent. Differences in excipients can affect pH, viscosity, osmolality, preservative effectiveness, drop size, and ocular tolerability.

Sulfite and preservative labeling

Removing sulfites or benzalkonium chloride may create a valuable product, but it can also require a separate stability and preservation package. A materially different inactive-ingredient profile may increase development complexity.

Container performance

Dropper tip geometry, delivered volume, bottle inversion behavior, and residual volume can affect dose delivery and patient acceptance. The container is a commercial differentiator and a CMC risk.

Market economics

Sulfacetamide ophthalmic products compete in a low-cost generic environment. Development economics are stronger when the sponsor has existing sterile ophthalmic capacity, a portfolio sales force, or a contract manufacturing platform.

What licensing deals and litigation affect BLEPH-10?

No major licensing transaction is inherent to the legacy sulfacetamide sodium molecule. A licensing opportunity would more likely involve:

• A preservative-free multidose dispensing platform.
• A sterile ophthalmic contract manufacturing arrangement.
• A sulfite-free stabilization technology.
• A low-drop-volume bottle.
• A hospital or retail generic distribution agreement.

No major publicly established litigation or settlement framework is central to the legacy BLEPH-10 formulation in the cited FDA materials. Litigation risk would increase if a company launched a differentiated preservative-free product protected by device, formulation, or manufacturing patents.

How strong is the BLEPH-10 patent estate?

The legacy patent estate is weak as a barrier to conventional generic entry. The stronger intellectual-property opportunity is a new product architecture.

IP strategy	Strength
Claim sulfacetamide sodium alone	Very weak
Claim a conventional 10% aqueous solution	Weak
Claim sulfite-free stability system	Moderate if technically unexpected
Claim preservative-free multidose delivery	Moderate to strong if device-specific
Claim improved drop-size and dosing system	Moderate
Claim manufacturing process with measurable quality benefit	Moderate
Claim broad treatment use	Weak to moderate, depending on prior art and listing

A new formulation patent should establish unexpected stability, improved ocular tolerability, reduced degradation, improved preservative effectiveness, or a device result that is not predictable from existing ophthalmic systems.

How does BLEPH-10 compare with competing ophthalmic antibacterials?

Sulfacetamide sodium competes with broader-use topical antibiotics such as trimethoprim-polymyxin B, fluoroquinolone ophthalmic products, and other prescription antibacterial solutions or ointments. Its advantages are established use, low formulation complexity, and potential low cost. Its disadvantages include sulfonamide hypersensitivity concerns, sulfite-related labeling issues in some formulations, and weaker modern physician preference than newer agents.

Product attribute	BLEPH-10	Newer ophthalmic antibacterials
Molecule maturity	Very high	High to moderate
Generic competition	High	Varies
Price potential	Low	Low to moderate
Preservative differentiation	Strong opportunity	Already developed in some products
Resistance positioning	Limited	Depends on active ingredient
Patent leverage	Low	Varies by product
Manufacturing complexity	Moderate	Moderate
Commercial differentiation	Formulation and delivery	Molecule, indication, delivery, or brand

What commercial opportunities exist for BLEPH-10?

The best opportunities are niche and execution-driven.

1. Preservative-free unit-dose product for sensitive ocular surfaces.
2. Sulfite-free solution for patients with sulfite concerns.
3. Preservative-free multidose bottle with controlled dispensing.
4. Pediatric and geriatric packaging with easier administration.
5. Hospital supply product with dependable availability.
6. Private-label or co-branded generic ophthalmic platform.
7. Combination portfolio with lubricants, lid hygiene products, or blepharitis therapies.
8. Contract-manufactured product for regional pharmaceutical companies.

Revenue exposure from a conventional generic launch is likely constrained by low pricing and existing competition. A differentiated product can improve gross margin, but the sponsor must support the premium with packaging, tolerability, availability, or channel-specific value.

Key Takeaways

• BLEPH-10 is a mature sulfacetamide sodium 10% ophthalmic solution.
• Conventional composition-of-matter and basic formulation patent protection are weak.
• The main technical opportunities involve preservative-free, sulfite-free, low-irritation, and controlled-drop formulations.
• Benzalkonium chloride and sulfite components are the most commercially relevant excipient targets.
• A preservative-free multidose container offers the strongest potential differentiation.
• Generic entry is technically feasible but requires sterile manufacturing, stability, preservation, and container-closure expertise.
• Biosimilar competition is irrelevant because BLEPH-10 is a small-molecule ophthalmic product.
• Licensing value is concentrated in dispensing technology, sterile fill-finish capacity, and differentiated excipient systems.
• A conventional generic is likely to compete on cost and availability. A reformulated product can compete on tolerability and dosing experience.

FAQs

Is BLEPH-10 preservative-free?

The answer depends on the specific marketed presentation. Public sulfacetamide sodium ophthalmic labeling has included benzalkonium chloride in some products. The exact inactive-ingredient list must be confirmed for the intended NDC and package size.[1][2]

Can sulfites be removed from a sulfacetamide ophthalmic solution?

Yes, but removal requires a new stability, impurity, preservation, and packaging development program. Sulfite removal is a formulation opportunity, not a simple label change.

Is BLEPH-10 eligible for a biosimilar?

No. Sulfacetamide sodium is a small-molecule active ingredient. A competing product would generally use an abbreviated new drug application pathway rather than the biosimilar pathway.

Can a preservative-free BLEPH-10 product receive patent protection?

Potentially. Protection is more plausible for a specific stabilizer system, multidose dispensing device, container configuration, or manufacturing process than for sulfacetamide sodium or a conventional 10% solution.

What is the main barrier to launching a BLEPH-10 generic?

The main barrier is validated sterile ophthalmic manufacturing combined with competitive market economics. Patent protection is less likely to be the primary barrier than CMC execution, supply reliability, and product differentiation.

References

1. U.S. Food and Drug Administration. (n.d.). BLEPH-10: Sulfacetamide sodium ophthalmic solution, USP, 10% prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. National Library of Medicine. (n.d.). Sulfacetamide sodium ophthalmic solution drug labeling. DailyMed. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2019). Ophthalmic drug products for topical ophthalmic administration: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ophthalmic-drug-products-topical-ophthalmic-administration-guidance-industry